Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure

NCT01082094 ↗

Phase 1 Completed 17 enrolled Juventas Therapeutics, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 1 study is to assess the safety, tolerability, and preliminary efficacy of single escalating doses of ACRX-100 delivered via endomyocardial injection in adults with ischemic heart failure.

Timeline

Start: 2010-02
Primary completion: 2012-01
Completion: 2012-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ACRX-100	Unknown	—	Other

Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure

Summary

Timeline

Drugs

Indications